Investor Presentaiton

110 Investor presentation Full year 2022 Growth momentum has increased driven by demographics and utilisation of full product portfolio International Operations is diverse and covers 190 markets Historic growth has been in the range of 5-10% Growth momentum in IO Novo NordiskⓇ >487m live with diabetes 16% 30% 16 12 >600m live with obesity 8 5% 4 IO's share of revenue FY 2022 اااس 26% 20% 20% 14% 10% 0 0% 2015 2022 Nov Nov 2019 2022 NAO 51% 49% ΙΟ Growth rate range NN Diabetes market share Market growth NN Diabetes growth NAO: North America Operations; IO: International Operations; Share of Growth not depicted due to high numbers; FY: Full Year Source (RHS): IQVIA Nov 2022, Value, MAT

View entire presentation